Directorio

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

We are doing this study to compare the usual treatment of Nivolumab and ipilimumab to using the usual treatment plus surgery for people with sarcomatoid mesothelioma. We want to find out if adding surgery to the immunotherapy regimen is effective in stabilizing this type of cancer.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.

We are doing this study to find out if an experimental gene therapy drug called ABBV-RGX-314 (the study drug) has similar effects to approved drugs, such as Lucentis® or Eylea® injections. The study drug will be injected into one eye with a Suprachoroidal Space (SCS) Microinjector®, which is an investigational needle device developed by Clearside Biomedical, Inc.

We are doing this study to see if the study drugs ABBV-400 and budigalimab, in combination with chemotherapy, are a safe and effective option for treating gastroesophageal cancer. We are also trying to find the best dose of ABBV-400 to use.

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating colorectal cancer when it is combined with the following standard-of-care drugs: 5-fluorouracil, folinic acid, and bevacizumab. We are also trying to find the best dose and frequency of ABBV-400 to use.